Aurobindo Pharma has received final approval from the US Food & Drug Administration to manufacture and market Repaglinide Tablets USP 0.5mg, 1 mg and 2mg. The product is ready for launch. The market size of the product is estimated to be $274 million for the twelve months ending November 2013 according to IMS.For more information call- 0731-6642300 or Visit https://www.epicresearch.co/
No comments:
Post a Comment